UroGen Pharma Ltd. (URGN) Total liabilities 2016–2025
UroGen Pharma Ltd. (URGN) total liabilities at each fiscal year-end, per SEC filings.
$305.9MFY2025 · since FY2016: $6.7M → $305.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $305.9M | +3.9% |
| FY2024 | $294.5M | +20.9% |
| FY2023 | $243.5M | +8.2% |
| FY2022 | $225.0M | +102.1% |
| FY2021 | $111.3M | +334.0% |
| FY2020 | $25.6M | +16.1% |
| FY2019 | $22.1M | +64.0% |
| FY2018 | $13.5M | +91.4% |
| FY2017 | $7.0M | +4.2% |
| FY2016 | $6.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More URGN financial trends
URGN RevenueURGN Net incomeURGN Net marginURGN Gross profitURGN Gross marginURGN Operating incomeURGN Operating marginURGN Operating cash flowURGN Free cash flowURGN Capital expendituresURGN Return on equityURGN Stock buybacksURGN Dividends paidURGN Total assetsURGN Shareholders’ equityURGN overview →